HAIRNA Exosome Hair Fill is a hair filler that helps restore the scalp. Thanks to the harmonious interaction between exosomes, growth factors, and active ingredients, this formula strengthens the scalp’s protective barrier, actively combats hair loss, and restores balance to an unhealthy scalp. HAIRNA Exosome Hair Fill is a preparation designed to rejuvenate the scalp and stimulate hair growth. The effectiveness of using the HAIRNA Exosome Hair Fill cocktail is an overall improvement in hair condition and thickness.
Benefits:
– Prevents hair loss
– Nourishes the scalp and adds shine to hair
– Strengthens hair structure
– Anti-inflammatory effect
– Accelerates wound healing
– Enhances the scalp’s protective barrier
Application method:
Mesotherapy:
1. Apply a topical anesthetic cream to the scalp.
2. After 30 minutes, rinse off the cream.
3. Then, clean the needle with alcohol and insert it into the syringe.
4. Inject the product into the target area using a 30G needle to a depth of 1-1.2 mm.
For best results, this process should be repeated once a week for 2-3 months.
Main ingredients:
Exosomes – revolutionary rejuvenation and powerful regeneration.
Copper tripeptide-1 stimulates collagen production, contributing to increased vitality and strength in hair.
Biotin – Known for its role in promoting hair growth and overall hair health.
Biotinoyltripeptide-1 helps reduce hair loss by contributing to thicker hair.
Thiamine diphosphate improves blood circulation in the scalp, supporting the health of hair follicles.
sh-Polypeptide-1 (FGF2) stimulates cell growth, helping to regenerate healthy hair cells.
Pyridoxine HCL – essential for maintaining a healthy scalp and preventing dryness.
Folic acid promotes cell division and supports the growth of healthy hair strands.
Pack:
1 x pre-filled syringe containing 2.5 ml.
This product is for professional use only.
By purchasing this product, you declare that you are a physician or aesthetic professional trained in aesthetic medicine.
Collapse









Reviews
There are no reviews yet.